These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 22732654

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
    Grupe M, Grunnet M, Bastlund JF, Jensen AA.
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336
    [Abstract] [Full Text] [Related]

  • 23. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.
    Coates KM, Flood P.
    Br J Pharmacol; 2001 Oct; 134(4):871-9. PubMed ID: 11606328
    [Abstract] [Full Text] [Related]

  • 24. Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors.
    Olsen JA, Kastrup JS, Peters D, Gajhede M, Balle T, Ahring PK.
    J Biol Chem; 2013 Dec 13; 288(50):35997-6006. PubMed ID: 24169695
    [Abstract] [Full Text] [Related]

  • 25. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes.
    Grønlien JH, Håkerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, Malysz J.
    Mol Pharmacol; 2007 Sep 13; 72(3):715-24. PubMed ID: 17565004
    [Abstract] [Full Text] [Related]

  • 26. Identification by virtual screening and functional characterisation of novel positive and negative allosteric modulators of the α7 nicotinic acetylcholine receptor.
    Smelt CLC, Sanders VR, Newcombe J, Burt RP, Sheppard TD, Topf M, Millar NS.
    Neuropharmacology; 2018 Sep 01; 139():194-204. PubMed ID: 30009834
    [Abstract] [Full Text] [Related]

  • 27. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
    Zwart R, van Kleef RG, Gotti C, Smulders CJ, Vijverberg HP.
    J Neurochem; 2000 Dec 01; 75(6):2492-500. PubMed ID: 11080202
    [Abstract] [Full Text] [Related]

  • 28. The Abeta1-42M35C mutated amyloid peptide Abeta1-42 and the 25-35 fragment fail to mimic the subtype-specificity of actions on recombinant human nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4).
    Pym LJ, Buckingham SD, Tsetlin V, Boyd CA, Sattelle DB.
    Neurosci Lett; 2007 Oct 29; 427(1):28-33. PubMed ID: 17945421
    [Abstract] [Full Text] [Related]

  • 29. Acute Administration of Desformylflustrabromine Relieves Chemically Induced Pain in CD-1 Mice.
    Weggel LA, Pandya AA.
    Molecules; 2019 Mar 07; 24(5):. PubMed ID: 30866543
    [Abstract] [Full Text] [Related]

  • 30. Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization.
    Collins T, Young GT, Millar NS.
    Neuropharmacology; 2011 Dec 07; 61(8):1306-13. PubMed ID: 21820451
    [Abstract] [Full Text] [Related]

  • 31. Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.
    Kowal NM, Ahring PK, Liao VWY, Indurti DC, Harvey BS, O'Connor SM, Chebib M, Olafsdottir ES, Balle T.
    Br J Pharmacol; 2018 Jul 07; 175(14):2911-2925. PubMed ID: 29669164
    [Abstract] [Full Text] [Related]

  • 32. Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.
    Hamouda AK, Wang ZJ, Stewart DS, Jain AD, Glennon RA, Cohen JB.
    Mol Pharmacol; 2015 Jul 07; 88(1):1-11. PubMed ID: 25870334
    [Abstract] [Full Text] [Related]

  • 33. Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
    Gill JK, Savolainen M, Young GT, Zwart R, Sher E, Millar NS.
    Proc Natl Acad Sci U S A; 2011 Apr 05; 108(14):5867-72. PubMed ID: 21436053
    [Abstract] [Full Text] [Related]

  • 34. Functions and pharmacology of α2β2 nicotinic acetylcholine receptors; in and out of the shadow of α4β2 nicotinic acetylcholine receptors.
    Papke RL.
    Biochem Pharmacol; 2024 Jul 05; 225():116263. PubMed ID: 38735444
    [Abstract] [Full Text] [Related]

  • 35. Action of nereistoxin on recombinant neuronal nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes.
    Raymond Delpech V, Ihara M, Coddou C, Matsuda K, Sattelle DB.
    Invert Neurosci; 2003 Nov 05; 5(1):29-35. PubMed ID: 14608492
    [Abstract] [Full Text] [Related]

  • 36. The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the alpha4beta2 receptor subtype.
    Papke RL, Webster JC, Lippiello PM, Bencherif M, Francis MM.
    J Neurochem; 2000 Jul 05; 75(1):204-16. PubMed ID: 10854263
    [Abstract] [Full Text] [Related]

  • 37. The subtype-selective nicotinic acetylcholine receptor positive allosteric potentiator 2087101 differentially facilitates neurotransmission in the brain.
    de Filippi G, Mogg AJ, Phillips KG, Zwart R, Sher E, Chen Y.
    Eur J Pharmacol; 2010 Sep 25; 643(2-3):218-24. PubMed ID: 20624387
    [Abstract] [Full Text] [Related]

  • 38. Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC.
    Norleans J, Wang J, Kuryatov A, Leffler A, Doebelin C, Kamenecka TM, Lindstrom J.
    J Biol Chem; 2019 Aug 09; 294(32):12132-12145. PubMed ID: 31221718
    [Abstract] [Full Text] [Related]

  • 39. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.
    Pandya A, Yakel JL.
    Biochem Pharmacol; 2011 Oct 15; 82(8):952-8. PubMed ID: 21596025
    [Abstract] [Full Text] [Related]

  • 40. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.
    Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI, Emkey R, Hollinshead SP, Dell CP, Baker SR, Sher E.
    J Pharmacol Exp Ther; 2006 Sep 15; 318(3):1108-17. PubMed ID: 16738207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.